We profiled the FAK inhibitor, VS4718, and the MEK inhibitors, GDC-0623 and trametinib, via dose–response across a panel of 14 patient-derived GBM stem cell models representing broad GBM heterogeneity (Figure 4A). The gene discussed is PTK2; the disease is glioblastoma.